Wall Street Zen Downgrades Predictive Oncology (NASDAQ:POAI) to Strong Sell

Predictive Oncology (NASDAQ:POAI) was downgraded by equities researchers at Wall Street Zen to a “strong sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Predictive Oncology in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Predictive Oncology Stock Performance

NASDAQ:POAI opened at $4.26 on Friday. The firm’s 50-day moving average is $9.01 and its 200-day moving average is $11.79. Predictive Oncology has a 52-week low of $3.88 and a 52-week high of $45.90. The company has a market cap of $14.44 million, a price-to-earnings ratio of -0.32 and a beta of 1.36.

Predictive Oncology (NASDAQ:POAI) last released its earnings results on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($3.17). Predictive Oncology had a negative net margin of 5,065.23% and a negative return on equity of 732.73%. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $1.50 million. Equities analysts predict that Predictive Oncology will post -2.08 EPS for the current year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.